PCOS Renamed PMOS: New Name, New Hope for 170 Million Women Worldwide

After a 14-year effort involving medical experts, patient advocacy groups, and women with lived experience, polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS), reflecting its broader hormonal and metabolic impact. The change, announced last week, aims to improve diagnosis, treatment, and public understanding of a condition affecting an estimated 170 million women worldwide. However, the UK’s National Health Service (NHS) has yet to update its public-facing resources, leaving patients and healthcare providers in potential confusion.

The new name, PMOS, was introduced to better capture the condition’s systemic effects beyond ovarian dysfunction, including metabolic and endocrine disruptions that contribute to long-term health risks such as type 2 diabetes, cardiovascular disease, and infertility. The renaming was spearheaded by a coalition of organizations, including the Endocrine Society, which published a statement emphasizing the need for clearer language to reduce diagnostic delays and stigma.

Despite the official change, the NHS website for England—one of the most widely consulted health resources in the UK—still refers exclusively to the condition as PCOS. A grassroots charity, Cysters, has criticized the delay, warning that outdated terminology could exacerbate barriers to care, particularly for marginalized communities already facing systemic inequities in healthcare access.

As an organisation rooted in reproductive and health justice, we welcome conversations around language that better reflect the realities and experiences of those living with PMOS/PCOS. But any name change must go beyond symbolism. Communities deserve clear, accessible and timely information so people are not left confused, excluded or struggling to access support and diagnosis.

— Neelam Heera-Shergill, CEO and founder of Cysters

The transition to PMOS is part of a broader push to modernize medical terminology, aligning with updated guidelines from organizations like the National Institute for Health and Care Excellence (NICE), which is expected to release revised PCOS/PMOS management recommendations later this year. The Endocrine Society’s official announcement highlighted that the new name acknowledges the condition’s role in disrupting multiple hormonal axes, including insulin resistance, adrenal function, and thyroid regulation.

Healthcare professionals, including general practitioners, are being advised to familiarize themselves with the change ahead of NICE’s guidelines. A practical update for GPs published by Pulse Today noted that while the Monash University PCOS guidelines remain the gold standard, the shift to PMOS will require adjustments in diagnostic criteria and patient communication. The update emphasized that symptoms such as irregular periods, excess androgen levels, and metabolic dysfunction remain central to diagnosis, though the broader systemic impact is now explicitly recognized.

Why the Name Change Matters

The renaming of PCOS to PMOS addresses long-standing critiques that the original term underestimated the condition’s complexity. Historically, PCOS was framed primarily as a reproductive health issue, leading to delayed or misdiagnoses in non-reproductive contexts. The new terminology underscores its role in metabolic and endocrine disorders, which may improve early intervention and tailored treatment plans.

For women and individuals assigned female at birth, the condition often goes undiagnosed for years, with symptoms dismissed as unrelated to hormonal imbalances. The World Health Organization estimates that PCOS/PMOS contributes to 70% of infertility cases linked to anovulation, as well as a 50% higher risk of type 2 diabetes compared to the general population. The renaming aims to shift perceptions of PCOS/PMOS from a “women’s health” issue to a systemic metabolic disorder requiring multidisciplinary care.

Challenges Ahead: Transition and Accessibility

The three-year transition period announced alongside the name change presents logistical challenges for healthcare systems, educational materials, and patient support networks. While the NHS has not yet committed to a timeline for updates, experts warn that fragmented communication could lead to patient confusion, particularly in primary care settings where terminology may vary between providers.

Caroline Andrews, a trustee of the charity Verity, acknowledged the need for a phased approach but stressed the importance of consistency in public health messaging. Any transition must prioritize clarity for patients, ensuring they are not left navigating outdated information while healthcare systems adapt, she stated. Verity, which supports over 90,000 individuals with PCOS/PMOS annually, is collaborating with the NHS to develop patient-friendly resources that reflect the new terminology.

Beyond the UK, the renaming is expected to influence global discussions on PCOS/PMOS, particularly in regions where diagnostic criteria and treatment protocols lag behind evidence-based guidelines. The Endocrine Society’s statement noted that the change aligns with similar efforts in Australia and the US, where medical societies have begun incorporating PMOS into clinical frameworks.

What Comes Next

In the immediate term, patients are advised to:

• Check with healthcare providers about whether their clinic or GP practice has adopted the new terminology.
• Review updated guidelines from NICE (expected late 2026) for changes in diagnostic criteria or treatment recommendations.
• Engage with advocacy groups like Cysters or Verity for support in navigating the transition.
• Monitor official NHS updates, particularly on the PCOS information page, for revisions.

For healthcare professionals, the shift to PMOS will require updating electronic health records, patient education materials, and referral pathways. Medical societies are urging institutions to treat the transition as an opportunity to re-evaluate diagnostic algorithms and integrate metabolic screening into standard PCOS/PMOS care plans.

The renaming of PCOS to PMOS marks a significant milestone in the recognition of a condition that has long been misunderstood and underdiagnosed. While the path to widespread adoption presents challenges, advocates emphasize that the change is not merely symbolic—it reflects a deeper commitment to addressing the full spectrum of health impacts faced by those living with the condition.